Market News / Story
ArriVent plunges as lead asset fails in late-stage cancer trial
Seeking Alpha ·
Seeking Alpha reports: ArriVent BioPharma lost more than 50% on Tuesday after announcing the failure of a late-stage trial for its lead candidate, firmonertinib, targeting a type of lung cancer. In a statement, the Pennsylvania-based biotech said that the oral therapy didn’t meet the primary endpoint of progression-free survival in its FURVENT Phase 3 trial for a subset of patients with non-squamous non-small cell lung cancer. FURVENT was designed to evaluate firmonertinib as a first-line…